Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2016-03-09

FDA Approved: ZALTRAP — Supplemental Application (sanofi-aventis U.S. LLC)

View source ↗

Summary

FDA approved a supplemental application for ZALTRAP (ziv-aflibercept) with labeling changes expanding/ updating its approved use.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Zaltrap (ramucirumab)

Snippet

SUPPL AP for ZALTRAP (ZIV-AFLIBERCEPT)